astrazeneca glp-1 AstraZeneca's elecoglipron just posted some of the most closely watched Phase IIb data of the year and it landed at the right conference. Results from the VISTA and SOLSTICE trials, published simultaneously AZ to terminate once-daily cotadutide

With rising global incidence and expanding patient populations, the therapeutic landscape for T2D has evolved rapidly.

Are people going blind from GLP-1 medications

Notably, no permanent treatment discontinuations or dose reductions due to gastrointestinal side effects were reported in ribupatide-treated participants

Learn about the factors that influence coverage, potential costs, and alternative options.

The FDA has granted accelerated approval of Wegovy (semaglutide) for adults with moderate to advanced metabolic dysfunction-associated steatohepatitis (MASH)

An active-comparator new user study design was used to minimise risks of confounding and time related biases from using real world studies of drug effects